Scientists have discovered that genes switch off as memories are being formed, allowing for new connections between nerve cells. The discovery could eventually lead to a key for treating conditions such as autism and dementia. Researchers studying honeybees during learning activities have shown that memory management in the bee brain is controlled by small genetic elements called microRNAs that help regulate gene expression.
One of the most mysterious forms of life may turn out to be a rich and untapped source of antibacterial drugs. The mysterious life form is Archaea, a family of single-celled organisms that thrive in environments like boiling hydrothermal pools and smoking deep sea vents which are too extreme for most other species to survive.
Powered lower limb prosthetics hold promise for improving the mobility of amputees, but errors in the technology may also cause some users to stumble or fall. New research examines exactly what happens when these technologies fail, with the goal of developing a new generation of more robust powered prostheses.
Scientists at SLAC National Accelerator Laboratory are combining the speed and precision of robots with one of the brightest x-ray lasers on the planet for pioneering studies of proteins important to biology and drug discovery. The new system uses robotics and other automated components to precisely maneuver delicate samples for study with the x-ray laser pulses at SLAC’s Linac Coherent Light Source.
Scientists from Lawrence Berkeley National Laboratory have learned new details about how an important tumor-suppressing protein, called p53, binds to the human genome. As with many things in life, they found that context makes a big difference. The researchers mapped the places where p53 binds to the genome in a human cancer cell line.
The next Ebola or the next SARS. Maybe even the next HIV. Even before the Ebola epidemic in West Africa is brought under control, public health officials are girding for the next health disaster. Ebola sprang from one of those blind spots, in an area that lacks the health systems needed to detect an outbreak before it becomes a crisis.
Scientists at The Scripps Research Institute (TSRI) have discovered how one gene is essential to hearing, uncovering a cause of deafness and suggesting new avenues for therapies. The new study, published in Neuron, shows how mutations in a gene called Tmie can cause deafness from birth. Underlining the critical nature of their findings, researchers were able to reintroduce the gene in mice and restore the process underpinning hearing.
Enzymes carry out fundamental biological processes such as photosynthesis, nitrogen fixation and respiration, with the help of clusters of metal atoms as "active" sites. But scientists lack basic information about their function because the states thought to be critical to their chemical abilities cannot be experimentally observed.
Researchers from Oregon State Univ. and other institutions have developed a new biomarker called “SDMA” that can provide earlier identification of chronic kidney disease in cats, which is one of the leading causes of their death. A new test based on this biomarker, when commercialized, should help pet owners and their veterinarians watch for this problem through periodic checkups, and treat it with diet or other therapies.
Recent studies showing acid ceramidase (AC) to be upregulated in melanoma, lung and prostate cancers have made the enzyme a desired target for novel synthetic inhibitor compounds. In Angewandte Chemie, scientists with the Univ. of California, Irvine School of Medicine and the Italian Institute of Technology describe the very first class of AC inhibitors that may aid in the efficacy of chemotherapies.
U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking such safeguards. The FDA approved Purdue Pharma's Hysingla ER for patients with severe, round-the-clock pain that cannot be managed with other treatments.
The R&D 100 Awards have a 50+ year history of recognizing excellence in innovation, earning the name the “Oscars of Invention." And at the annual event, the high rollers of the science and technology industry were honored on stage for their innovative, high-tech products and processes that are, or will, make a difference in our everyday lives.
Flexible electronic sensors based on paper have the potential to cut the price of a wide range of medical tools, from helpful robots to diagnostic tests. Scientists have now developed a fast, low-cost way of making these sensors by directly printing conductive ink on paper.
New research has found that one of the world's most prolific bacteria manages to afflict humans, animals and even plants by way of a mechanism not before seen in any infectious microorganism—a sense of touch. This unique ability helps make the bacteria Pseudomonas aeruginosa ubiquitous, but it also might leave these antibiotic-resistant organisms vulnerable to a new form of treatment.
A widely presumed problem of aging is that the brain becomes less flexible or plastic, and that learning may therefore become more difficult. A new study led by Brown Univ. researchers contradicts that notion with a finding that plasticity did occur in seniors who learned a task well, but it occurred in a different part of the brain than in younger people.
The government proposed new rules Wednesday to make it easier for doctors and patients to learn if clinical trials of treatments worked or not. Thousands of Americans participate in clinical trials every year, testing new treatments, comparing old ones or helping to uncover general knowledge about health. Many of the studies are reported in scientific journals and trumpeted in the news.
The discovery of the innate immunity system’s role in mobilizing the body’s defenses against invading microorganisms has been long studied at Yale Univ. Now in Nature Immunology, Yale researchers have discovered a surprising twist to the story that may open a new avenue in the fight against HIV.
Univ. of California, Los Angeles biochemists have created the largest-ever protein that self-assembles into a molecular “cage.” The research could lead to synthetic vaccines that protect people from the flu, HIV and other diseases. At a size hundreds of times smaller than a human cell, it also could lead to new methods of delivering pharmaceuticals inside of cells, or to the creation of new nanoscale materials.
Scientists have made high-resolution x-ray laser images of an intact cellular structure much faster and more efficiently than ever possible before. The results are an important step toward atomic-scale imaging of intact biological particles, including viruses and bacteria. The technique was demonstrated at the Linac Coherent Light Source at the SLAC National Accelerator Laboratory.
A major challenge faced by the pharmaceutical industry has been how to rationally design and select protein molecules to create effective biologic drug therapies while reducing unintended side effects—a challenge that has largely been addressed through costly guess–and–check experiments. Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard Univ. offer a new approach.
Researchers at the Univ. of Michigan have discovered how a previously unknown hormone serves as a messenger from fat cells to the liver and are investigating the potential of developing a new treatment for metabolic disorders. Jiandie Lin of the Life Sciences Institute described how in mice the hormone, NRG4, is secreted by so-called brown fat cells and communicates with the liver to regulate the conversion of sugar into fat.
For such humble creatures, single-celled paramecia have remarkable sensory systems. Give them a sharp jab on the nose, they back up and swim away. Jab them in the behind, they speed up their swimming to escape. But according to new research, when paramecia encounter flat surfaces, they’re at the mercy of the laws of physics.
A coalition of companies and aid groups announced plans Tuesday to test experimental drugs and collect blood plasma from Ebola survivors to treat new victims of the disease in West Africa. Plasma from survivors contains antibodies, substances the immune system makes to fight the virus.
Scientists at The Scripps Research Institute have identified weak spots on the surface of Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. The study provides a revealing 3-D picture of how the ZMapp antibodies bind to Ebola virus.
Massachusetts Institute of Technology chemists have developed new nanoparticles that can simultaneously perform magnetic resonance imaging (MRI) and fluorescent imaging in living animals. Such particles could help scientists to track specific molecules produced in the body, monitor a tumor’s environment, or determine whether drugs have successfully reached their targets.